Item 9 Labs Corp. Announces New CFO

SCOTTSDALE, Arizona, October 15, 2018 – Item 9 Labs Corp. (OTC: INLB) (“Item 9 Labs” or the “Company”), a leading provider of comfortable cannabis health solutions for the modern consumer through the development of innovative products and proprietary delivery platforms, today announced the resignation of Jessica Smith (“Smith”) as Chief Financial Officer, Secretary and Treasurer of the Company. Smith’s resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.

“Jessica has been a valuable asset to the Company for over 6 years and while we are saddened to see her go, we are grateful for her many years of committed service to the Company. We wish Jessica the very best in her future endeavors” said Jeffrey Rassas, Chief Strategy Officer.

On October 15, 2018, Mr. Robert “Bobby” Mikkelsen  (“Mr. Mikkelsen”) was appointed to serve as the Chief Financial Officer of the Company and has accepted such appointment. Mr. Mikkelsen has been working with the Company in the capacity of Vice President of Finance since April 2018. The biography for Mr. Mikkelsen is set forth below.

Robert E. Mikkelsen, 37, is a Certified Public Accountant (“CPA”) in the State of Arizona, received his Bachelor’s degree in accounting in 2004 from the Eller College of Business, University of Arizona.  After graduating from The Eller College of Business Mr. Mikkelsen went on to work as an auditor for Henry & Horne, LLP in Arizona. Moving up the ranks quickly to Audit Manager, Mr. Mikkelsen utilized his analytical thinking and problem-solving skills to implement effective and efficient changes to the audit process as well as add value to the clients he served. Mr. Mikkelsen has worked with a client base that is diverse in both size and industry, working with small non-profits, large government agencies, and medium sized business, including those in health care, mental health, and pharmaceutical industries. After 11 years, in January 2016, Mr. Mikkelsen started his own firm, Mikkelsen CPA, LLC which focuses on serving clients in various industries with accounting, tax, and CFO Solutions. Mr. Mikkelsen is a member of the American Institute of Certified Public Accountants.

About Item 9 Labs Corp.:

Item 9 Labs Corp. (OTC: INLB) creates comfortable cannabis health solutions for the modern consumer by developing innovative products and proprietary delivery platforms. The Company is focused on the development of technology and products that administer high-quality medical marijuana through a novel intra-nasal delivery system to deliver significant health benefits. The Company is headquartered in Southern Arizona where it owns and operates 50 acres, one of the largest properties in the U.S. zoned to grow and cultivate the medical marijuana flower. Item 9 has a proven track record of providing consumers with high-quality medical marijuana flower and products focused on organic, cost-effective solutions for whole body health. By combining high-quality, medical-grade product with the Company’s proprietary nasal mucus-membrane delivery system, Item 9 plans to produce the industry’s first market medicated nasal delivery device that administers specific cannabinoid dosing to meet the growing demand of today’s modern cannabis consumer. For more information, visit us online at www.Item9labscorp.com and www.Item9labs.com.

Forward-Looking Statement: This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties, including, but not limited to, risks and effects of legal and administrative proceedings and governmental regulation, especially in a foreign country, future financial and operational results, competition, general economic conditions, proposed transactions that are not legally binding obligations of the company and the ability to manage and continue growth. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include the introduction of new technology, market conditions and those set forth in reports or documents we file from time to time with the SEC. We undertake no obligation to revise or update such statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Media Contact:
Investor Relations:
Jeffrey Rassás
(480)463-4246 or 1-833-TOPMEDS (1-833-867-6337)
Email: jeffrey@item9labs.com